The growth hormone somatropin is in shortage, according to the American Society of Health-System Pharmacists (ASHP) and the US Food and Drug Administration (FDA). Resupply and recovery dates range from late this month to December.
Somatropin manufacturers Novo Nordisk, Eli Lilly, and Pfizer have all reported shortages.
Novo Nordisk's 15 milligram (mg)/1.5 milliliter (mL) Norditropin Flexpro pen injector has been only intermittently available, which the company says is due to increased demand and manufacturing delays, according to ASHP. The 10 mg/1.5 mL, 30 mg/3 mL, and 5 mg/1.5 mL formulations are still available, the site says, although the FDA's site lists all four presentations as in shortage.
Eli Lilly's Humatrope 12-mg and 24-mg kits have been in shortage since January due to delays at the contract manufacturer, and Eli Lilly's Humatrope has been unavailable since February for the same reason. Pfizer's 5 mg/mL and 12 mg/mL two-chamber cartridges and its Miniquick presentations are out of stock due to increased demand and other reasons, according to the company.
Genentech (Nutropin NuSpin) and Sandoz (Omnitrope) formulations are still available.
Somatropin is used to treat adults and children with a growth hormone deficiency and in children with some conditions that may slow or prevent normal growth and development.